Abstract
Omalizumab, a glycoprotein based biotherapeutics, is one of the most frequently used targeted antibody biopharmaceutical to reduce asthma exacerbation......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
